New concepts on progressive multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 7, Issue 3, 2007, Pages 239-244

  Lassmann, Hans ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; CHRONICITY; DEMYELINATION; DIFFUSE AXONAL INJURY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; INFLAMMATION; LYMPH FOLLICLE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROIMAGING; PATHOGENESIS; RELAPSE; REVIEW; T LYMPHOCYTE; WHITE MATTER;

CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS;

EID: 34249734136     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-007-0036-0     Document Type: Review

References (51)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker B: Multiple sclerosis. N Engl J Med 2000, 343:938-952.
2. Grossman RI, Braffman BH, Brorson JR, et al.: Multiple sclerosis: serial study of gadolinium enhanced MR imaging. Radiology 1988, 169:117-122.
3. Miller DH, Rudge P, Johnson G, et al.: Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988, 111:927-939.
4. Lucchinetti C, Brück W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717. injury within the NAWM.
5. Trapp BD, Peterson J, Ransohoff RM, et al.: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
6. Mews I, Bergmann M, Bunkowski S, et al.: Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998, 4:55-62.
7. Ormerod IE, Miller DH, McDonald WI, et al.: The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 1987, 110:1579-1616.
8. Polman CH, O'Connor PW, Havdrova E, et al.: A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
9. Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430-1438.
10. Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
11. Leary SM, Miller DH, Stevenson VL, et al.: Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2006, 60:44-51.
12. Coles AJ, Cox A, Le Page E, et al.: The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J Neurol 2006, 253:98-108.
13. Thompson AJ, Kermode AG, Wicks D, et al.: Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991, 29:53-62.
14. Thompson AJ, Polman CH, Miller DH, et al.: Primary progressive multiple sclerosis. Brain 1997, 120:1085-1096.
15. Fu L, Matthews PM, De-Stefano N, et al.: Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998, 121:103-113.
16. Ingle GT, Stevenson VL, Miller DH, Thompson AJ: Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003, 126:2528-2536.
17. Rocca MA, Iannucci G, Rovaris M, et al.: Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2.visible lesions - a diffusion tensor MR study. J Neurol 2003, 250:456-460.
18. Rovaris M, Bozzali M, Santuccio G, et al.: In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain 2001, 124:2540-2549.
19. Zamvil SS, Steinman L: Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 2003, 38:685-688.
20. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al.: Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712
21. Prineas JW, Kwon EE, Cho ES, et al.: Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001, 50:646-657.
22. Prineas JW, Wright RG: Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978, 38:409-421.
23. Brownell B, Hughes JT: The distribution of plaques in the cerebrum in multiple scleosis. J Neurol Neurosurg Psychiat 1962, 25:315-320.
24. Bo L, Vedeler CA, Nyland HI, et al.: Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003, 62:723-732.
25. Peterson JW, Bo L, Mork S, et al.: Transsected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
26. Kutzelnigg A, Lassmann H: Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 2006, 245:123-126.
27. Kutzelnigg A, Faber-Rod JC, Bauer J, et al.: Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol2007, 17:38-44.
28. Bo L, Vedeler CA, Nyland H, et al.: Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003, 9:323-331.
29. Merkler D, Ernsting T, Kerschensteiner M, et al.: A new focal EAE model of cortical demyelination: MS-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006, 129:1972-1983.
30. Allen IV, McKeown SR: A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979, 41:81-91.
31. Allen IV, McQuid S, Miradkhur M, Nevin G: Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol Sci 2001, 22:141-144.
32. Jellinger K: Einige morphologische Aspekte der Multiplen Sklerose. Wien Z Nervenheilk 1969, II(Suppl):12-37.
33. Bjartmar C, Wujek JR, Trapp BD: Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003, 206:165-171.
34. Evangelou N, Konz D, Esiri MM, et al.: Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000, 123:1845-1849.
35. Evangelou N, DeLuca GC, Owens T, Esiri MM: Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of focal lesions. Brain 2005, 128:29-34.
36. Kwon EE, Prineas JW: Blood brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropath Exp Neurol 1994, 53:625-636.
37. Kirk J, Plumb J, Mirakhur M, McQuaid S: Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003, 201:319-327.
38. Hochmeister S, Grundtner R, Bauer J, et al.: Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropath Exp Neurol 2006, 65:855-865.
39. Serafini B, Rosicarelli B, Magliozzi R, et al.: Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
40. Aloisi F, Pujol-Borrell R: Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6:205-217.
41. Meinl E, Krumbholz M, Hohlfeld R: B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 2006, 59:880-892.
42. Metz I, Lucchinetti CF, Openshaw H, et al.: Multiple sclerosis pathology after autologous stem cell transplantation: ongoing demyelination and neurodegeneration despite suppressed inflammation. Brain 2007, February 9 [Epub ahead of print].
43. Burt RK, Cohen BA, Russell E, et al.: Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003, 102:2373-2378.
44. Ozawa K, Suchanek G, Breitschopf H, et al.: Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
45. Aboul-Enein F, Rauschka H, Kornel B, et al.: Preferential loss of myelin associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropath Exp Neurol 2003, 62:25-33.
46. Stadelmann C, Ludwin S, Tabira T, et al.: Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005, 128:979-987.
47. Smith KJ, Lassmann H: The role of nitric oxide in multiple sclerosis. Lancet Neurology 2002, 1:232-241.
48. Graumann U, Reynolds R, Steck AJ, et al.: Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003, 13:554-573.
49. Dutta R, McDonough J, Yin X, et al.: Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis. Ann Neurol 2006, 59:478-489.
50. Evangelou N, Konz D, Esiri MM, et al.: Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001, 124:1813-1820.
51. Stys PK: General mechanisms of axonal damage and its prevention. J Neurol Sci 2005, 133:3-13.